Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 177 HER2-positive Breast Cancer 16 Neoplasms 11 Neoplasm Metastasis 10 Prostatic Neoplasms 7 Ovarian Neoplasms 7 Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Pancreatic Neoplasms 5 Inflammatory Breast Neoplasms 5 Colonic Neoplasms 5 Brain Neoplasms 5 Triple Negative Breast Neoplasms 4 Multiple Myeloma 4 Hematologic Neoplasms 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Urinary Bladder Neoplasms 3 Solid Tumor 3 Rectal Neoplasms 3 Pathologic Complete Response 3 Lymphoma, Non-Hodgkin 3 Lung Neoplasms 3 HER2-positive Early Breast Cancer 3 Esophageal Neoplasms 3 Breast Neoplasms, Male 3 Biliary Tract Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Salivary Gland Neoplasms 2 Locally Advanced Breast Cancer 2

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × pertuzumab × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡